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Abstract
Traditionally, phase I clinical trial designs determine a maximum tolerated dose
of an experimental cytotoxic agent based on a fixed schedule, usually one course
consisting of multiple administrations, while varying the dose per administration
between patients. However, in actual medical practice patients often receive sev-
eral courses of treatment, and some patients may receive one or more dose re-
ductions due to low-grade (non-dose limiting) toxicity in previous courses. As a
result, the overall risk of toxicity for each patient is a function of both the sched-
ule and the dose used at each adminstration. We propose a new paradigm for
Phase I clinical trials that allows both the dose per administration and the sched-
ule to vary, making treatment two-dimensional. We provide an outcome-adaptive
Bayesian design that simultaneously optimizes both dose and schedule in terms
of the overall risk of toxicity, based on time-to-toxicity outcomes. The method is
illustrated with a trial of an agent hypothesized to prolong cancer remission after
allogeneic bone marrow transplantation, and a simulation study in the context of
this trial is presented.
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SUMMARY. Traditionally, phase I clinical trial designs determine a maximum tol-
erated dose of an experimental cytotoxic agent based on a fixed schedule, usually
one course consisting of multiple administrations, while varying the dose per ad-
ministration between patients. However, in actual medical practice patients often
receive several courses of treatment, and some patients may receive one or more
dose reductions due to low-grade (non-dose limiting) toxicity in previous courses.
As a result, the overall risk of toxicity for each patient is a function of both the
schedule and the dose used at each adminstration. We propose a new paradigm for
Phase I clinical trials that allows both the dose per administration and the sched-
ule to vary, making treatment two-dimensional. We provide an outcome-adaptive
Bayesian design that simultaneously optimizes both dose and schedule in terms
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of the overall risk of toxicity, based on time-to-toxicity outcomes. The method is
illustrated with a trial of an agent hypothesized to prolong cancer remission after
allogeneic bone marrow transplantation, and a simulation study in the context of
this trial is presented.
KEY WORDS: Adaptive design; phase I trial; bone marrow transplantation; dose
escalation; CRM; maximum tolerated dose; hypomethylation; chromatin
1. Introduction
Conventional phase I clinical trials determine the maximum tolerated dose (MTD)
of a new agent by characterizing patient outcome as a binary indicator of whether
toxicity occurs within a short time period from the start of therapy. Generally,
the MTD is the highest dose that does not present a practical limitation to ther-
apy (Storer, 1989; Goodman et al., 1995; Babb et al., 1998). This approach has
seen widespread use largely because it facilitates adaptive dose-finding methods
that successively use the doses and outcomes of previous patients to select doses
for new patients. A limitation of these methods is that they typically base dose-
finding on a single course of therapy, whereas multiple courses typically are used
in medical practice. As a result, the MTD based on a single course of treatment
may prove to be overly toxic when given over multiple courses. For example, if
conventional dose-finding is done with a fixed schedule consisting of one course
when in fact a safe dose d∗ exists with three courses and this combination has
substantive anti-disease effect whereas d∗ with only one course does not, then the
conventional MTD of one course may lead to the erroneous conclusion in later
studies that the agent is ineffective. Similarly, if conventional dose-finding is done
with four courses and it turns out that the lowest dose is excessively toxic, then it
may be concluded erroneously that the agent is unsafe at any dose simply because
shorter schedules were not examined.
Recently, a new phase I method was proposed that determines a maximum
2
http://biostats.bepress.com/umichbiostat/paper63
tolerated schedule (MTS), rather than a conventional MTD (Braun et al., 2005).
The MTS is defined as the maximum number of courses that can be given without
causing unacceptable cumulative toxicity. The model and method account for the
patient’s sequence of administrations and allows the number of courses to vary so
that an optimal schedule may be determined. However, while this method allows
the number of courses to vary, it requires the dose used in each administration to
be fixed. Thus, if the fixed dose is ill-chosen, the MTS may be far from optimal.
One may easily imagine examples similar to those given above by switching the
roles of dose and schedule.
This paper is motivated by the problems, noted above, that arise in phase I tri-
als when either the schedule is fixed and aMTD is found, or the per-administration
dose is fixed and a MTS is found. We propose a new paradigm for Phase I clin-
ical trials that simultaneously optimizes both the dose per adminstration and the
overall schedule. The design examines a matrix of possible (dose, schedule) com-
binations. Each patient is assigned a combination using previous patients’ data,
with decision criteria based on the posterior under a Bayesian model using time-
to-toxicity as the outcome. The goal is to determine a maximum tolerated dose
and schedule (MTDS) in terms of the overall risk of toxicity. Our formulation al-
lows both the dose and the timing of each administration to vary between patients.
This accommodates settings where a patient’s dose per administration is decreased
if a low grade toxicity is observed, and we also allow a patient’s actual doses or
administration times to deviate from planned values due to logistical difficulties
or human error. Consequently, although the design examines a predetermined ma-
trix of (dose, schedule) combinations, the model allows each patient’s treatment
to consist of an arbitrary sequence of administration times and a corresponding
sequence of doses, so that the likelihood reflects the actual data in the trial.
Section 2 describes the trial that motivated this research and that will be used
for illustration. Section 3 presents notation and probability models, including
3
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methods for eliciting and calibrating priors. Section 4 provides criteria for eval-
uating (dose,schedule) pairs and rules for trial conduct. Section 5 illustrates the
method via simulations as applied to an allogeneic cell transplantation trial, and
we conclude with a discussion in Section 6.
2. Motivating Example
In allogeneic blood or bone marrow cell transplantation (allotx) for treatment of
leukemia, a patient (host) receives cells (the graft) from a donor who has been
matched on a number of human leukocyte antigen sites. The graft contains T-
cells and natural killer cells that coordinate a positive immune response that kills
leukemia cells, called a graft-versus-leukemia (GVL) effect. However, allotx re-
cipients who initially respond to treatment have a substantial risk of disease re-
currence due to proliferation of residual leukemia cells. As a result, investigators
continue to seek agents that can be given to allotx recipients after they achieve a
response in order to reduce the risk of disease recurrence.
Epigenetic DNA changes are reversible modifications of the DNA-histone
complex that do not require alterations in nucleotide sequences (Das and Singal,
2004). Addition of a methyl group to gene promoter areas (DNA methylation) is
associated with gene silencing, and abnormal methylation patterns are commonly
seen in cancer cells. Hypermethylation of promoter regions appears to suppress
genes involved in leukemic cell growth. Methylation is maintained by the enzyme
cytosine DNA methyltransferase, with inhibition of this enzyme leading to hy-
pomethylation and subsequent reactivation of tumor suppressor genes. Vidaza
R©
(5-azacitidine) inibits DNA methyltransferase by forming covalent adducts with
the enzyme, activating silent genes that may lead to cell death, and also may in-
duce phenotypic modification of the leukemic cells to facilitate immune recogni-
tion and potentiation of the donor cells’ GVL effect. Vidaza
R© has been approved
by the U.S. Food and Drug Administration for the treatment of myelodysplastic
syndrome (MDS), a blood cell disease that often progresses to acute myelogenous
4
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leukemia (AML). The recommended dose and schedule for MDS patients is 75
mg/m2 given subcutaneously, daily for seven days, with this seven-day cycle re-
peated every four weeks. No data exist, however, on what a safe dose and schedule
for AML patients might be.
The method described here was motivated by the desire to design a phase I
trial to optimize both the schedule and the dose per administration of Vidaza
R©
in AML. The trial currently is ongoing at M.D. Anderson Cancer Center. For
the purpose of determining an optimal (dose,schedule) pair, “toxicity” is defined
as any of the following adverse events (AEs): (1) severe (grade 3 or 4) toxicity
of the kidney, liver, heart or lung, or neural toxicity, as defined by standard NCI
grading criteria; (2) severe graft-versus-host disease; (3) systemic infection that
cannot be resolved by antibiotics within 2 weeks; (4) severe hematologic toxicity,
with thrombocytopenia and or neutropenia or (5) an AE of any of these types that
leads to subsequent delay or termination of therapy, or a dose reduction. Each
patient may receive up to four courses of therapy, and the dose may be reduced
up to two times for reasons other than the toxicities listed above. Thus, a patient’s
treatment may consist of an initial dose and the times at which it was adminis-
tered, a second, possibly lower dose, along with its administration times, and so
on, up to four courses. In practice, a patient’s administration times may deviate
from the planned schedule due to practical difficulties in adhering to the schedule
over several months of therapy, or intentional delay of a planned course by the
physician to allow a patient to recover from a low grade toxicity. Additionally, a
patient may receive the wrong dose due to human error. Thus, an important fea-
ture of our model is that it accommodates each patient’s actual treatment sequence
by accounting for the contribution of each dose and its time of administration to
the patient’s overall risk of toxicity.
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3. Probability Model
3.1 General Form of the Hazard and Likelihood
Suppose one wishes to evaluate J doses, d1 < d2 < · · · < dJ , and K nested
schedules, s(1), · · · , s(K). The kth schedule is a sequence of administration times,
s(k) = (s1, s2, . . . , sm(k)),with s(k) a subsequence of s(k+1) for each k = 1, . . . , K−
1, and m(1) < m(2) · · · < m(K). Here, “dose” is the amount of the agent given
at each administration. For example, a patient given d2 under schedule s(3) =
(s1, s2, . . . , sm(3)) receives the cumulative amount d2m(3) of the agent inm(3) suc-
cessive administrations, unless therapy is terminated early due to toxicity. Thus,
a patient’s assigned treatment is indexed by the pair (j, k), representing (dj, s(k)),
there are M = JK such pairs under consideration, and the total amount of the
agent given to the patient increases with both dose and schedule.
In the motivating study, there are three doses of interest: 8, 16 and 24 mg/m2,
and four schedules, for a total of M = 12 combinations. One course consists
of 5 consecutive daily administrations. Ideally, the first course begins 40 days
post-transplant, although this may vary since the physician may decide to delay
administration due to early complications, such as infection. We thus define the
time to toxicity from the time when the first course is actually begun, the patient’s
enrollment time. The first schedule, s(1) = (0, 1, 2, 3, 4), consists of one course.
The second schedule includes one additional course starting 28 days after the
beginning of s(1), so that s(2) = (0, 1, 2, 3, 4, 28, 29, 30, 31, 32) = (s(1), s(1)+28).
The third and fourth schedules are defined similarly, with s(3) = (s(1), s(1) +
28, s(1) + 56) and s(4) = (s(1), s(1) + 28, s(1) + 56, s(1) + 84). Figure 1 provides a
schematic representation of the 12 (dose,schedule) combinations evaluated in the
trial. We denote the maximum length of follow-up for each patient specified by
the investigators by τ , which should be large enough to include toxicities arising
from the longest schedule, s(K). In the motivating trial, τ = 116 days, which is 28
days after the start of the fourth course.
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[Figure 1 about here.]
Our model generalizes that used by Braun et al. (2005) by extending it to
allow the dose per administration to vary and also using a new parameterization
to facilitate computation. While other models are possible, we use this model here
because it is robust (section 6.4, Table 4, below) and because our primary focus
is the new algorithm for optimizing (dose,schedule). Let t∗ denote a time, from
the start of the trial, when one evaluates the data and either assigns a particular
pair (j, k) to the next patient or terminates the trial early if no pair is acceptable.
Denote by e the study time when the patient’s therapy begins. We denote the
time to toxicity by Y and let Y o be the patient’s observed time from e to either
toxicity or last follow up at study time t∗. Thus, Y o = Y if e + Y ≤ t∗ or
Y o = t∗ − e if e + Y > t∗. Let δ = I(Y o = Y ) indicate that the patient has
toxicity by study time t∗. Let h(u | θ, d) denote the hazard of toxicity associated
with a single administration of dose d of the agent given u days previously, where
θ is a vector of model parameters; we define h(u | θ, d) = 0 for u < 0. Let
s = (s1, · · · , sk) denote the patient’s sequence of administration times and ds
= (dj(s1), · · · , dj(sk)) the corresponding doses up to study time t∗. Thus, j(s`)
indexes the dose given to the patient at time s` after entry, at study time e + s`.
The overall hazard of toxicity at study time t∗ for a patient treated with schedule
s and doses ds is λ(t∗ | θ, s,ds) =
∑k
`=1 h(t
∗− e− s` | θ, dj(s`)). Consequently,
the patient’s cumulative hazard function at t∗ is Λ(t∗ | θ, s,ds) =
∑k
`=1 H(t
∗ −
e − s` | θ, dj(s`)), where H(x | θ, d) =
∫ x
0
h(u | θ, d)du, with survivor function
Pr(Y > t∗ | θ, s,ds) = F¯ (t∗ | θ, s,ds) = exp{−Λ(t∗ | θ, s,ds)} and density
f(t∗ | θ, s,ds) = λ(t∗ | θ, s,ds)F¯ (t∗ | θ, s,ds). Let n∗ denote the number of
patients enrolled up to t∗. For the ith patient, ei is the entry time, the sequence
of administration times up to t∗ is ei + si = (ei + si,1, · · · , ei + si,ki), and dsi =
(dj(si,1), · · · , dj(si,ki )) is the corresponding sequence of doses, i = 1, · · · , n∗. For
treatment sequences (si,dsi) and outcome data (Y
o
i , δi), patient i has likelihood
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Li(θ|Y oi , δi, si,dsi) = λ(Y oi | θ, si,dsi)δi F¯ (Y oi | θ, si,dsi),, and the overall
likelihood at t∗ is L(θ | datan∗) =
∏n∗
i=1 Li(θ|Y oi , δi, si,dsi).
This model accommodates each patient’s actual sequence of administration
times and doses, which often deviate from his/her planned treatment. For ex-
ample, suppose a patient’s planned treatment was two courses with 24 mg/m2 at
each of the 10 administrations, but the patient began the first course two days
late, was reduced to 8 mg/m2 in the second course due to a grade 2 infection,
and was given 16 mg/m2 by mistake at the tenth administration. Then the pa-
tient’s actual treatment would be s = (2, 3, 4, 5, 6, 30, 31, 32, 33, 34) and ds =
(24, 24, 24, 24, 24, 8, 8, 8, 8, 16). While this is not any of the 12 (dose, schedule)
combinations being studied in the Vidaza
R© trial (Figure 1), the model allows this
patient’s data to be included in the likelihood.
It may be unclear how to score Y for some patients. The definition of toxicity
in the Vidaza
R© trial includes grade 2 toxicities that cannot be resolved therapeu-
tically within 2 weeks from onset or that necessitate a dose reduction. We chose
to score such toxicities as occurring at the time of initial onset. For example, if a
patient has a grade 2 thrombocytopenia starting at day 10 of therapy that persists
beyond day 24 and requires a dose reduction, we define Y o = 10 and δ = 1.
However, if the thrombocytopenia is resolved by day 24, then it is not scored as
a toxicity, and at day 24 we define Y o = 24 and δ = 0, provided that no other
toxicity has occurred. This approach is conservative in that toxicity is assumed to
have occurred as soon as possible.
3.2 Single Administration Hazard Function
The probability model is determined by the particular form of h, for which we
employ a reparameterized version of the triangular hazard function used by Braun
et al. (2005). In this model, for each per-administration dose j = 1, · · · , J , denote
θj = (aj, bj, cj), with θ = {θ1, . . . ,θJ} and each entry of θ positive-valued. The
8
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hazard of toxicity associated with a single administration of dose dj is
h(u | θj) =

2aj
bj+cj
u
bj
0 ≤ u ≤ bj
2aj
bj+cj
bj+cj−u
cj
bj < u ≤ bj + cj
0 u > bj + cj or u < 0.
(1)
This is a triangle having base of length bj+cj and area equal to aj, with the height
of the triangle, 2aj/(bj + cj), occurring at u = bj . The area of this triangle is the
cumulative single-administration hazard Hj = aj for dose dj . The constraint that
the per-administration cumulative hazard of toxicity increases with dose says that
a1 < a2 < · · · < aJ . In some applications, however, the risk of toxicity may reach
a plateau or may even decrease with a higher dose or longer schedule, such as in
studies of anti-infection agents that have adverse effects, and such an ordering
constraint is inappropriate.
3.3 Establishing Priors
To enforce the constraint a1 < a2 < . . . < aJ so that F (τ | θ, dj, s(k)), the
probability of toxicity by τ , increases with dose, we let a∗j = aj − aj−1 for
j ≥ 2, with a∗1 = a1. We assume that (a∗1, · · · , a∗J) follows a J-variate lognor-
mal prior with all correlations equal to zero, although a posteriori the a∗j ’s may
be correlated. Denoting the marginals by a∗j ∼ LN(µa∗j , σ2a), this implies that
E(a∗j ) = exp(µa∗j + σ
2
a/2) and var(a
∗
j ) = exp(2µa∗j + σ
2
a){exp(σ2a) − 1}. Simi-
larly, (b1, · · · , bJ) and (c1, · · · , cJ) each follow J-variate lognormal priors, with
marginals bj ∼ LN(µbj , σ2b ) and cj ∼ LN(µcj , σ2c ) for each j. We chose the mul-
tivariate lognormal for its generality and tractability. Denoting µj = (µa∗j , µbj , µcj )
andσ2 = (σ2a, σ
2
b , σ
2
c ), the model has 3J location hyperparameters,µ = (µ1, · · · ,µJ)
and 3 scale hyperparameters, σ2 = (σ2a, σ
2
b , σ
2
c ); we denote θ˜ = (µ,σ
2). In Sec-
tion 5, we will illustrate how to determine θ˜ in the context of the application.
Appropriate values for the prior mean and variance parameters may be elicited
from the investigators in many ways (Gelman et al., 2004), although in general,
it is easiest to elicit values on domains with which the investigator is familiar
9
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(Tsutakawa and Lin, 1986). Thus, we elicit the expected values of the following
three quantities for each dose j = 1, · · · , J :
(1) ξj,1 = −log{1 − Fj(τ | s(1),θ)} = m(1)aj , the transformed probability of
toxicity by time τ under the shortest schedule s(1)
(2) ξj,2, the time until the maximum hazard is reached for one administration of
dose j, and
(3) ξj,3, the time from the peak of the hazard until the hazard vanishes com-
pletely or becomes negligible for a single administration of dose j .
In practice, one elicits the mean probabilityE{Fj(τ | s(1),θ) | θ˜} and then derives
E{ξj,1 | θ˜} ≈ − log[1 − E{Fj(τ | s(1),θ) | θ˜}]. We will use the superscript (e)
to denote elicited values, with ξ(e)j,` the elicited mean of ξj,`, ` = 1, 2, 3.
We derive additional functions of the hyperparameter vector θ˜ by assuming
that ξj,1 has an inverse Gamma (IG) distribution with variance (ξ
(e)
j,1 )
2/(ν1 − 1),
and that ξj,2 and ξj,3 have IG distributions with respective variances (ξ
(e)
j,2 )
2/(ν2−1)
and (ξ(e)j,3 )
2/(ν2−1). We use the same value ν2 in the distributions of ξj,2 and ξj,3 as
they both describe time durations and differ in nature from ξj,1. Since ξj,1, ξj,2, and
ξj,3 correspond respectively to m(1)aj , bj , and cj , we use the following method-
of-moments approach to solve for θ˜ by equating the elicited moments of ξj,1, ξj,2,
and ξj,3 to their corresponding theoretical moments. Denoting ξ
(e)
0,1 = 0, we solve
the following set of equations for θ˜:
exp(µa∗j + σ
2
a/2) = (ξ
(e)
j,1 − ξ(e)j−1,1)/m(1) (2)
exp(2µa∗j + σ
2
a){exp(σ2a)− 1} = [(ξ(e)j,1 − ξ(e)j−1,1)/m(1)]
2
/(ν1 − 1) (3)
exp(µbj + σ
2
b/2) = ξ
(e)
j,2 (4)
exp(2µbj + σ
2
b ){exp(σ2b )− 1} = (ξ(e)j,2 )2/(ν2 − 1) (5)
exp(µcj + σ
2
c/2) = ξ
(e)
j,3 (6)
exp(2µcj + σ
2
c ){exp(σ2c )− 1} = (ξ(e)j,3 )2/(ν2 − 1). (7)
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Comparing Equations (2) and (3) shows that exp(σ2a)− 1 = (ν1− 1)−1, hence
σ2a = log{ν1/(ν1−1)}, which is a function solely of ν1. Comparing Equations (4)-
(5) and Equations (6)-(7), shows that σ2b = σ
2
c = log{ν2/(ν2 − 1)}. Thus, ν1 and
ν2 are tuning parameters that determine the informativeness of the prior. Solving
for the prior location parameters gives µa∗j = log([ξ
(e)
j,1 − ξ(e)j−1,1]/m(1))−σ2a/2, µbj
= log(ξ(e)j,2 )−σ2b/2 and µcj = log(ξ(e)j,3 )−σ2c/2. Thus, σ2 is determined by the tuning
parameters ν1 and ν2, and given σ2, the elicited quantities are used to determine
the prior location parameters µ.
4. Choosing (Dose, Schedule) Combinations
Because trial conduct uses decision criteria based on the most recent posterior
computed when a new patient is accrued, the data must be monitored continu-
ously, making the design computationally intensive. We compute the posterior of
θ using Markov Chain Monte Carlo methods as described in the Appendix. For
each (j, k), we base decisions on Fjk(θ) = F (τ | θ, dj, s(k)), the cumulative prob-
ability of toxicity within τ days after enrollment for a patient treated with dose j
and schedule k. We will say that the pair (j, k) is acceptable if:
Pr{Fjk(θ) > Fmax | datan∗} < pu, (8)
where Fmax is a fixed upper bound on the probability of toxicity by τ specified
by the physician and pu is a fixed decision cut-off, typically set to 0.80 or larger.
This is similar to the criterion used for defining acceptable toxicity used by Thall
and Cook (2004), in the context of dose-finding based on efficacy and toxicity.
We denote the set of acceptable (dose, schedule) combinations byO∗. IfO∗ is the
empty set, then all (j, k) combinations are unacceptable and the trial is terminated.
If O∗ has two or more elements, then we compute the distance measure
d∗jk = |E{Fjk(θ) | datan∗} − pio | , (9)
for each (j, k) ∈ O∗, where pio is a desired target for Pr(Y < τ) specified by the
physician. We assign patient n∗ + 1 to the element of O∗ having smallest d∗jk.
11
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To protect patient safety, we constrain O∗ to include only (j, k) pairs with
doses that are at most one dose above and/or one schedule longer than those com-
binations already assigned to previous patients. If (j∗, k∗) is the pair that was
assigned to the previous subject, and no pair with higher dose or longer schedule
has previously been tried, then the next patient may be assigned any pair (j, k) for
which j ≤ j∗ + 1 and k ≤ k∗ + 1; we call this the ”do not skip” rule. Thus, one
may de-escalate, stay at (j∗, k∗), increase either dose or schedule by one level,
or increase both dose and schedule by one level, as shown by Figure 1. These
restrictions only apply to untried (j, k) pairs when escalating, and we place no
restriction on de-escalation of either dose or schedule. Combining all of the above
criteria and rules, our algorithm for trial conduct is as follows:
TRIAL CONDUCT
1. Treat the first patient at the lowest (dose, schedule) pair, (j, k) = (1, 1).
2. For each patient after the first, based on the current posterior of θ, determine
the set, O∗, of acceptable (j, k) combinations.
3. If O∗ is empty, then stop the trial and conclude that no (j, k) combination is
acceptable.
4. If O∗ is not empty, then assign the next patient to the element of O∗ with
smallest d∗jk, i.e., the combination whose posterior mean cumulative probability
of toxicity by τ is closest to pio.
5. If the study is not terminated before N patients have been enrolled and fully
evaluated with follow-up to τ , select the pair (j∗, k∗) that minimizes d∗jk as the
optimal (dose, schedule) combination.
For example, suppose that the first patient has been assigned to combination
(1, 1) and has not experienced toxicity. Due to the ”do not skip” rule, there are four
possible (dose,schedule) combinations for the next patient: O∗= {(1, 1), (1, 2),
12
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(2, 1), (2, 2)}. If we assign the second patient to combination (2, 1), and both
enrolled patients have not experienced toxicity when the third patient is enrolled,
then there are now six possible (dose,schedule) combinations for the third patient:
O∗= {(1, 1), (1, 2), (2, 1), (2, 2), (3, 1), (3, 2)}. This process is repeated with all
successively enrolled patients. Note that if (j, k) is determined to be unsafe by
Equation (8), then all pairs (j′, k′) with j′ ≥ j and k′ ≥ k must be unsafe.
5. Application
5.1 Design and Priors
The Vidaza
R© trial has three doses, d1 = 8, d2 = 16, and d3 = 24 mg/m2 and
four schedules with m(1) = 5, m(2) = 10, m(3) = 15, or m(4) = 20 admin-
istrations. The trial will enroll a maximum of N = 60 patients, with each pa-
tient followed for up to τ = 116 days. Using the trial conduct algorithm given
above, a (dose, schedule) combination is assigned to each new patient at the time
of his/her enrollment. The goal is to find a (dose,schedule) combination with
mean probability of toxicity by τ closest to pio = 0.30. The investigators believed
that the single-administration hazards for the three doses have expected peaks at
ξ
(e)
1,2 = 18, ξ
(e)
2,2 = 14, and ξ
(e)
3,2 = 10 days, respectively, with expected remain-
ing durations of ξ(e)1,3 = 10, ξ
(e)
2,3 = 14, and ξ
(e)
3,3 = 18 days. They also believed
that the expected probabilities of toxicity by 116 days for the three doses under
the shortest schedule are 0.20, 0.25, and 0.30, so that ξ(e)1,1 = −log(1 − 0.20),
ξ
(e)
2,1 = −log(1 − 0.25), and ξ(e)3,1 = −log(1 − 0.30). We derived θ˜ using this
elicited information as described in Section 3.3. The prior is characterized by
σ2a = σ
2
b = σ
2
c = 1.1, µ1 = (−3.66, 2.34, 1.75), µ2 = (−4.90, 2.09, 2.09),
µ3 = (−4.83, 1.75, 2.34). The safety criterion parameters for applying Equation
(4) were defined to be Fmax = 0.30 and pu = 0.80, so that a pair (j, k) is deemed
acceptable if less than 80% of the posterior mass of Fjk(θ) is above 0.30.
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5.2 Simulation Design
For the simulation study, we specified seven scenarios in terms of fixed true prob-
abilities of toxicity by day τ = 116, F truejk , for each (j, k). These scenarios are
summarized in Table 1 and illustrated by Figure 2. In Scenario 1, all 12 combina-
tions are safe, with F truejk ≤ 0.30, and the pairs (2, 4) and (3, 4) have F truejk closest
to 0.30. Scenarios 2 and 3 have several combinations with F truejk > 0.30, and all
12 combinations are toxic in scenario 4. In each of scenarios 5-7, combination
(2, 2) has F true22 = 0.30, but the scenarios differ in terms of how the F
true
jk values
of the other combinations vary around combination (2, 2).
[Table 1 about here.]
[Figure 2 about here.]
Based on input from the principal investigator, patient inter-arrival times were
simulated from an exponential distribution with mean of 2 weeks, reflecting an
accrual rate of about 2 patients per month, and we simulated 10% of all toxicities
to be low-grade, which are classified as dose-limiting at their onset if they fail to
resolve within two weeks. Thus, there is a two-week delay in the recording of
toxicities that began as low-grade toxicities.
We determined the values ν1, ν2 and pu used for the actual trial by first running
an extensive series of preliminary simulations using candidate values 1.1 ≤ ν1 ≤
3, 1.1 ≤ ν2 ≤ 14, and pu ∈ {0.70, 0.75, 0.80, 0.85, 0.90}. Initially, we examined
multiple combinations of the three parameters under scenario 4, our “worst-case”
scenario, and we selected a set of (ν1, ν2, pu) combinations to ensure a high prob-
ability (≥ 90%) of stopping early, to ensure a safe design. Once we found a subset
of safe (ν1, ν2, pu) combinations, we ran additional simulations using those com-
binations under each of the other scenarios to identify final values giving a design
with good properties under all scenarios. We found that ν1 = 1.5, ν2 = 1.5 and
pu = 0.80 reliably chooses (j, k) pairs with F truejk close to the targeted pi
o = 0.30
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in each of the non-worst case scenarios, while forcing early termination of the
study with at least 90% probability under scenario 4.
To examine the design’s robustness, we generated the Yi’s from each of sev-
eral different parameterizations of Weibull, exponential, and lognormal distribu-
tions under each scenario. In Tables 2 and 3, we report simulation results for an
exponential distribution with scale parameter chosen so that each F truejk equalled
the value specified in Table 1. Table 4 summarizes results under scenario 5 when
the Yi’s are generated from a Weibull distribution with shape parameter 0.4 and
a lognormal distribution with variance equal to that of the exponential. The scale
parameters of the Weibull and lognormal distributions were chosen so that F truejk
equalled the value specified in Table 1.
5.3 Simulation Results
Table 2 gives the selection frequency and the mean number of patients assigned to
each (dose, schedule) pair under each of the scenarios using the proposed design,
referred to as “MTDS.” As a basis for comparison, we also include results for a
conventional Phase I dose-finding design using the CRM (O’Quigley et al. (1990))
with the schedule fixed at schedule 4, assuming Pr(Yi ≤ 116 | dj, schedule 4) =
p
exp(α)
j for j = 1, 2, 3, with (p1, p2, p3) = (0.10, 0.30, 0.50), and α following a
normal prior with mean 0 and variance 2. Table 3 displays summary statistics for
both the MTDS and CRM designs under all seven scenarios. We consider (dose,
schedule) combinations with .20 ≤ F truejk ≤ .40 to be acceptable choices, with
boldfaced values in Table 2 corresponding to such combinations.
[Table 2 about here.]
[Table 3 about here.]
[Table 4 about here.]
In scenario 1, the MTDS design identifies one of the four acceptable combi-
nations as optimal 87% of the time, with on average about 38 patients assigned to
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one of these four combinations. The CRM assigns all 60 patients to an acceptable
combination, because in this case the CRM design fortuitously only examines
schedule 4. In scenario 2, one of the five acceptable combinations is identified as
optimal by the MTDS design in 81% of the simulations, with an average of nearly
42 patients assigned to one of these five combinations and around 7 patients as-
signed to combinations with F truejk > 0.40. Because the CRM design is limited
to doses with schedule 4, it can possibly find only the one acceptable combina-
tion (1,4) in scenario 2, which it identifies as the MTD 66% of the time, with 41
patients assigned to that combination. The CRM terminates early with no dose se-
lected 16% of the time, in contrast to 0% for the MTDS design, because the other
two doses are extremely toxic under schedule 4. That is, there is a probability 0.16
that a truly safe agent, when appropriately administered, will be abandoned based
on a conventional Phase I trial using the CRM. The limitations of fixing schedule
and only varying dose are further illustrated by Table 3. In particular, the CRM
has probability 0 of selecting an acceptable dose under each of scenarios 3, 6 and
7, where all of the acceptable doses are at schedules below schedule 4.
In scenario 3, the MTDS design identifies one of the four acceptable combina-
tions as optimal 88% of the time, with about 43 patients assigned to one of these
four combinations and 13 patients assigned to combinations with F truejk > 0.40.
Because all three doses are unacceptably toxic under schedule 4 in scenario 3,
the CRM is unable to find an acceptable dose simply because it never examines
a lower schedule. In scenario 3, the CRM exposes on average nearly 17 patients
to toxic combinations with 55% of them experiencing toxicity, and nearly always
terminates early with all combinations deemed unacceptable. In scenario 4, where
no combination is acceptable, 29 patients on average are enrolled under the MTDS
design before the study terminates, in contrast to only 14 patients under the CRM.
However, in the scenario where all combinations are overly toxic the MTDS de-
sign assigns a majority of patients only to combination (1,1) and its closest neigh-
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bors, with the overall incidence of toxicities similar between the MTDS and CRM
designs.
Scenarios 5-7 illustrate the MTDSmethod for different distributions of accept-
able (dose,schedule) pairs over the matrix of 12 pairs studied. Tables 2 and 3 show
that the MTDS reliably identifies acceptable pairs in all of these scenarios. The
conclusions reached from scenarios 1-4 are re-emphasized: because it does not
allow schedule to vary, a conventional CRM dose-finding design is likely to as-
sign a majority of patients to sub-optimal doses and is often unable to identify an
optimal (dose,schedule) pair. In contrast, the MTDS design assigns more patients
to acceptable combinations and often has a much greater likelihood of selecting a
combination suitable for further study.
A critical issue illustrated by the simulations is that the MTDS method is su-
perior to the CRM, or any method that searches for an optimal dose but does not
allow schedule to vary. The point is simply that, if the optimal (dose,schedule)
combination occurs at a schedule different from the fixed schedule assumed by
a method that only varies dose, such a method will have probability 0 of find-
ing the optimal combination, as was the case with CRM under scenarios 3, 6 and
7. Similarly, the MTDS method also is superior to the MTS method of Braun
et al. (2005), which fixes dose while only varying schedule. If the fixed dose is
suboptimal for all schedules, the MTS method will have probability 0 of finding
the optimal combination. We ran additional simulations (not shown) under each
scenario in Table 2 using an MTS design that examined all four schedules but
assigned all subjects to the same dose of 24 mg/m2 (final column of Table 1). In
scenario 3, in which 24 mg/m2 is toxic with all four schedules, the MTS design
identified the slightly toxic combination (3, 1) as optimal in 41% of simulations
and treated an average of 29 subjects with that combination, compared to 29% of
simulations and 12 subjects with the MTDS design (see Table 2). More strikingly,
in scenarios 5 and 7, where the MTS design is restricted to excessively toxic com-
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binations, this design terminated the trial 83% and 96% of the time, respectively,
with the false negative conclusion that no optimal combination existed and thus
the agent should not be studied in further clinical trials.
5.4 Robustness
Table 4 gives results for the MTDS design under scenario 5 with toxicity times
generated from Weibull, exponential, and lognormal distributions, described ear-
lier. The first four rows replicate the values displayed in Table 2. Table 4 indicates
that the performance of the MTDS method varies very little with the time-to-event
distribution, in terms of selection of acceptable (dose, schedule) pairs and num-
bers of patients assigned. Results for other time-to-event distributions and other
scenarios, not shown, were very similar to those presented in Table 4.
[Table 5 about here.]
To study the effects of maximum sample size, we simulated the trial using
the MTDS method with N = 40, 60 or 80. In scenario 1, the MTDS method
identified combination (3, 4) as optimal 32%, 44%, and 44% of the time with N
= 40, 60, and 80, respectively. In scenario 4, where no combination is safe, the
trial was terminated early 80%, 90%, and 96% of the time. In scenario 5, the four
acceptable combinations were identified as optimal in 64%, 71%, and 79% of the
time. Thus, although the design performs best with N = 80, our selected sample
size of N = 60 provides very desirable operating characteristics and improves
substantively upon N = 40.
6. Discussion
We have proposed a new paradigm for phase I clinical trials aiming to identify a
best (dose, schedule) combination. The specific model and parameterization used
here were selected for tractability and robustness, although other models certainly
are possible. We also examined a version of our design that does not allow “di-
agonal” escalation, that is, increasing both dose and schedule simultaneously, in
18
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order to protect patient safety when escalating. However, this restriction slowed
escalation so severely that far too many patients were assigned to sub-optimal
combinations and too few were assigned to optimal combinations. One also may
impose the safety constraint that escalation from the current combination (j∗, k∗)
cannot occur until a cohort of at least M patients have been assigned to (j∗, k∗),
analogous to the usual approach in conventional Phase I designs. However, we
found thatM = 1 yielded a safe design with good operating characteristics.
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Appendix
We used Markov Chain Monte Carlo (MCMC) with Gibbs sampling for integrat-
ing posterior quantities over the parameter space. For each integral, we generated
a series of random vectors of model parameters distributed proportionally to the
posterior integrand (likelihood times prior), with each series initialized by using
the mode. At the start of the trial, we initialized the posterior integrand mode to be
the same as the prior mode. When a new patient enrolled, the mode was updated
by random sampling around the previous mode. We worked in terms of the log of
the model parameters in order to generate all random values from normal distribu-
tions. We used two levels of sampling around the previous mode to ensure a good
approximation. The first level generates 10,000 normally distributed samples us-
ing a large variance for each parameter, roughly two orders of magnitude larger
than that parameter’s prior variance. In the rare case that this procedure failed to
find a mode, we increased the variance and the number of samples and repeated.
The second level takes 5000 more samples around the best mode approximation
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found at the first level, using the same variance. For the Gibbs sampling, the sub-
step of drawing from the conditional distribution uses importance sampling with
a symmetric normal proposal distribution. For each parameter θi, i = 1, 2, . . . 9,
we generated θ˜i ∼ N(θi, si), in which si is approximately the prior standard devi-
ation. Denoting θ˜ = (θ1, ..., θi−1, θ˜i, ..., θ9), we computed A = min{1, q(θ˜|data)/
q(θ|data)}, in which q(·) is the posterior integrand, and accepted θ˜i as the new θi
with probability A. MCMC convergence was monitored by comparing the Monte
Carlo standard error (MCSE) to the standard deviation of the decision variables
(i.e., the posterior cumulative probabilities of toxicity.) We began with 4000 sam-
ples and gradually reduced this to a minimum of 1000 samples until the MCSE
was ≤ 3% of the posterior standard deviation. Using the batch-means method to
estimate the MCSE (with batch size 50), we observed that 1000 random samples
were enough to keep the error ratio below 3%. We also used these samples to
construct the posterior marginal distribution of each model parameter and confirm
that each was a proper distribution with a unimodal shape.
References
BABB, J., A. ROGATKO, and S. ZACKS (1998). Cancer phase I clinical trials:
efficient dose escalation with overdose control. Statistics in Medicine 17, 1103–
1120.
BRAUN, T. M., Z. YUAN, and P. F. THALL (2005). Determining a maximum
tolerated schedule of a cytotoxic agent. Biometrics 61, 335–343.
DAS, P. M. and R. SINGAL (2004). DNA methylation and cancer. Journal of
Clinical Oncology 22, 4632–4642.
GELMAN, A., J. B. CARLIN, H. S. STERN, and D. B. RUBIN (2004). Bayesian
Data Analysis, 2nd edition. Chapman and Hall/CRC.
20
http://biostats.bepress.com/umichbiostat/paper63
GOODMAN, S., M. ZAHURAK, and S. PIANTADOSI (1995). Some pratical im-
provements in the continual reassessment method for phase I studies. Statistics
in Medicine 14, 1149–1161.
O’QUIGLEY, J., M. PEPE, and L. FISHER (1990). Continual reassessment
method: a practial design for phase I clinical trials in cancer. Biometrics 46,
33–48.
ROBERT, C. P. and G. CASELLA (1999). Monte Carlo Statistical Methods. New
York: Springer.
STORER, B. E. (1989). Design and analysis of Phase I clinical trials. Biomet-
rics 45, 925–937.
THALL, P. F. and J. D. COOK (2004). Dose-finding based on efficacy-toxicity
trade-offs. Biometrics 60, 684–693.
TSUTAKAWA, R. K. and H. Y. LIN (1986). Bayesian estimation of item response
curves. Psychometrika 51, 251–267.
21
Hosted by The Berkeley Electronic Press
Figure 1. Schematic representation of study.
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Figure 2. The fixed toxicity probabilities of each (dose, schedule) pair under
each of scenario in the simulation study. The dashed horizontal line represents the
target toxicity probability 0.30.
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Table 1
The fixed toxicity probabilities of each (dose, schedule) pair under each of
scenario in the simulation study.
Dose (mg/m2)
Scenario Schedule 8 16 24
1 4 0.22 0.26 0.30
3 0.16 0.18 0.23
2 0.09 0.12 0.18
1 0.05 0.07 0.11
2 4 0.31 0.45 0.62
3 0.18 0.32 0.54
2 0.09 0.21 0.40
1 0.03 0.14 0.28
3 4 0.55 0.62 0.72
3 0.45 0.50 0.62
2 0.30 0.32 0.50
1 0.10 0.26 0.35
4 4 0.57 0.73 0.78
3 0.55 0.65 0.75
2 0.53 0.60 0.65
1 0.50 0.54 0.58
5 4 0.30 0.48 0.70
3 0.14 0.32 0.55
2 0.12 0.30 0.48
1 0.10 0.28 0.45
6 4 0.50 0.60 0.75
3 0.30 0.50 0.60
2 0.12 0.30 0.50
1 0.03 0.15 0.30
7 4 0.10 0.60 0.70
3 0.05 0.50 0.60
2 0.03 0.30 0.55
1 0.01 0.10 0.50
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Table 2
Simulation results for the MTDS method and the CRM used within schedule 4.
For each (dose,schedule) pair, column (a) gives the selection percentage and
column (b) gives the mean number of patients assigned to the pair. Boldface
values correspond to pairs with toxicity probability between 0.20 and 0.40.
Dose (mg/m2)
8 16 24
Scenario Method Schedule (a) (b) (a) (b) (a) (b)
1 MTDS 4 0.02 3.5 0.16 10.1 0.44 13.1
3 0.01 2.6 0.06 6.4 0.25 11.4
2 0.00 1.6 0.00 3.5 0.05 6.5
1 0.00 1.0 0.00 0.1 0.00 0.3
CRM 4 0.47 30.6 0.31 17.8 0.19 10.3
2 MTDS 4 0.17 8.6 0.08 5.7 0.00 0.2
3 0.10 6.7 0.29 11.7 0.01 1.3
2 0.00 2.8 0.19 10.6 0.13 8.7
1 0.00 1.1 0.00 0.5 0.03 2.2
CRM 4 0.66 41.2 0.18 12.1 0.00 0.4
3 MTDS 4 0.01 2.9 0.00 0.5 0.00 0.0
3 0.06 6.1 0.01 1.6 0.00 0.0
2 0.26 13.7 0.14 9.9 0.01 1.7
1 0.03 3.3 0.19 7.3 0.29 12.4
CRM 4 0.03 15.6 0.00 1.1 0.00 0.0
4 MTDS 4 0.00 0.8 0.00 0.0 0.00 0.0
3 0.00 1.7 0.00 0.2 0.00 0.0
2 0.00 3.7 0.00 2.0 0.00 0.2
1 0.08 11.1 0.02 5.1 0.00 3.7
CRM 4 0.01 13.8 0.00 0.5 0.00 0.0
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Table 2 (continued)
Dose (mg/m2)
8 16 24
Scenario Method Schedule (a) (b) (a) (b) (a) (b)
5 MTDS 4 0.19 8.8 0.04 3.7 0.00 0.1
3 0.09 6.5 0.19 9.7 0.00 0.7
2 0.01 3.4 0.24 12.3 0.06 5.8
1 0.00 1.4 0.09 3.1 0.08 4.6
CRM 4 0.72 43.2 0.15 11.0 0.00 0.2
6 MTDS 4 0.09 6.9 0.00 0.9 0.00 0.0
3 0.32 12.9 0.03 3.2 0.00 0.2
2 0.13 9.3 0.29 15.0 0.01 3.0
1 0.00 1.2 0.00 1.4 0.11 6.1
CRM 4 0.08 20.6 0.00 1.7 0.00 0.0
7 MTDS 4 0.03 6.1 0.01 2.2 0.00 0.0
3 0.00 2.7 0.09 8.3 0.00 0.4
2 0.00 1.5 0.54 20.9 0.01 5.3
1 0.00 1.0 0.13 3.5 0.19 8.2
CRM 4 0.77 40.1 0.23 19.6 0.00 0.2
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Table 3
Summary statistics for the MTDS and CRM designs under each scenario.
S c e n a r i o
Method 1 2 3 4 5 6 7
Probability of Selecting MTDS 0.87 0.81 0.88 n/a 0.71 0.72 0.54
an Acceptable Dose CRM 0.97 0.66 0.00 n/a 0.72 0.00 0.00
Probability of Selecting MTDS 0.00 0.00 0.01 0.90 0.00 0.00 0.00
No Dose CRM 0.03 0.16 0.97 0.99 0.13 0.92 0.00
Mean Number of MTDS 60.0 60.0 59.5 28.7 60.0 60.0 60.0
Patients Enrolled CRM 58.7 53.6 16.7 14.3 54.5 22.4 59.9
Observed Incidence MTDS 0.22 0.29 0.34 0.54 0.31 0.31 0.33
of Toxicity CRM 0.25 0.34 0.55 0.58 0.34 0.51 0.27
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Table 4
Simulation results for scenario 5 under different time to toxicity distributions. For
each (dose,schedule) pair, column (a) gives the selection percentage, and column
(b) gives the mean number of patients assigned to the pair. Boldface values
correspond to pairs with cumulative toxicity probability between 0.20 and 0.40.
Dose (mg/m2)
Time-to-Event 8 16 24
Distribution Schedule (a) (b) (a) (b) (a) (b)
Exponential 4 0.19 8.8 0.04 3.7 0.00 0.1
3 0.09 6.5 0.19 9.7 0.00 0.7
2 0.01 3.4 0.24 12.3 0.06 5.8
1 0.00 1.4 0.09 3.1 0.08 4.6
Weibull 4 0.25 9.4 0.03 2.0 0.00 0.0
3 0.11 8.4 0.16 7.5 0.00 0.2
2 0.03 4.4 0.20 11.7 0.03 4.0
1 0.00 2.2 0.12 4.9 0.08 4.9
Lognormal 4 0.18 9.0 0.07 5.5 0.00 0.1
3 0.07 5.7 0.17 9.3 0.00 1.2
2 0.01 2.9 0.27 12.2 0.04 6.6
1 0.00 1.2 0.07 1.9 0.10 4.4
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